Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
Financial Results:
- Glenmark Pharmaceuticals Ltd reported Revenues for Q1FY24 of ₹3,402.00 Crores up from ₹2,777.00 Crore year on year, a rise of 22.51%.
- Total Expenses for Q1FY24 of ₹3,037.00 Crores up from ₹2,553.00 Crores year on year, a rise of 18.96%.
- Consolidated Net Profit of ₹173.00 Crores down 18.01% from ₹211.00 Crores in the same quarter of the previous year.
- The Earnings per Share is ₹5.31, down 22.14% from ₹6.82 in the same quarter of the previous year.